Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Responder rates to fampridine differ between clinical subgroups of MS patients and patient reported outcome influences treatment decision making.

Multiple sclerosis and related disorders - 1 Feb 2020

van Munster C E P, Kaya L, Lam K H, Kalkers N F, Killestein J, Uitdehaag B M J

Abstract excerpt

BACKGROUND: Fampridine is an effective treatment to improve ambulation for some multiple sclerosis (MS) patients. Remarkable discrepancies exist between responder rates in clinical trials and the proportion of patients continuing treatment in clinical practice. This may be related to clinical phenotypes of MS patients, and the influence of patient reported outcome (PRO) on treatment decision making. OBJECTIVE: To...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Decision-Making
Share to Follow-Up Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Multiple Sclerosis, Chronic Progressive

Share to Multiple Sclerosis, Relapsing-Remitting

Share to Patient Reported Outcome Measures

Share to Phenotype

Share to Potassium Channel Blockers

Share to Severity of Illness Index

Source

Identifiers

PMID: 31731213
DOI: 10.1016/j.msard.2019.101489

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Responder rates to fampridine differ between clinical subgroups of MS patients and patient reported outcome influences treatment decision making.PMID 31731213Read ↗

Validating therapy decisions by reasons for therapy switch in relapsing-remitting multiple sclerosisSemantic proximity Read ↗

Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study.Semantic proximity Read ↗

Regulator's view on the scientific and regulatory challenges in new mobility outcomes & PROsSemantic proximity Read ↗

MultiSCRIPT-Cycle 1- A Pragmatic trial embedded within the Swiss Multiple Sclerosis Cohort (SMSC) on neurofilament light chain monitoring to inform personalized treatment decisions in Multiple Sclerosis: a study protocol for a randomized clinical trialSemantic proximity Read ↗

Composite endpoints to detect treatment effects on MS disability progression. Lessons from phase III trial dataSemantic proximity Read ↗

The Effect of Nurse Practitioner (NP-led) Care on Health-Related Quality of Life in People with Multiple Sclerosis - A Randomized TrialSemantic proximity Read ↗

Response to vitamin B12 and folic acid in myalgic encephalomyelitis and fibromyalgia.Semantic proximity Read ↗

Double-blind, randomized controlled trial of therapeutic plasma exchanges vs sham exchanges in moderate-to-severe relapses of multiple sclerosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.